These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 34209109)
21. Interactions between inflammation and lipid metabolism: relevance for efficacy of anti-inflammatory drugs in the treatment of atherosclerosis. van Diepen JA; Berbée JF; Havekes LM; Rensen PC Atherosclerosis; 2013 Jun; 228(2):306-15. PubMed ID: 23518178 [TBL] [Abstract][Full Text] [Related]
22. Therapies targeting innate immunity for fighting inflammation in atherosclerosis. Mendel I; Yacov N; Harats D; Breitbart E Curr Pharm Des; 2015; 21(9):1185-95. PubMed ID: 25312734 [TBL] [Abstract][Full Text] [Related]
23. Cytokines and Immune Responses in Murine Atherosclerosis. Kusters PJ; Lutgens E Methods Mol Biol; 2015; 1339():17-40. PubMed ID: 26445779 [TBL] [Abstract][Full Text] [Related]
28. Atherosclerosis - A matter of unresolved inflammation. Viola J; Soehnlein O Semin Immunol; 2015 May; 27(3):184-93. PubMed ID: 25865626 [TBL] [Abstract][Full Text] [Related]
29. Research Progress of Mechanisms and Drug Therapy For Atherosclerosis on Toll-Like Receptor Pathway. Yin QY; Zhao B; Qiu YY; Fei YX; Hu YH; Li YM J Cardiovasc Pharmacol; 2019 Nov; 74(5):379-388. PubMed ID: 31730559 [TBL] [Abstract][Full Text] [Related]
30. The Beneficial Therapy with Colchicine for Atherosclerosis via Anti-inflammation and Decrease in Hypertriglyceridemia. Spartalis M; Spartalis E; Tzatzaki E; Tsilimigras DI; Moris D; Kontogiannis C; Kaminiotis VV; Paschou SA; Chatzidou S; Siasos G; Voudris V; Iliopoulos DC Cardiovasc Hematol Agents Med Chem; 2018; 16(2):74-80. PubMed ID: 30526472 [TBL] [Abstract][Full Text] [Related]
31. Atherosclerosis: perspectives of anti-inflammatory therapy. Nasonov EL; Popkova TV Ter Arkh; 2018 May; 90(5):4-12. PubMed ID: 30701884 [TBL] [Abstract][Full Text] [Related]
32. The NLRP3 inflammasome and the emerging role of colchicine to inhibit atherosclerosis-associated inflammation. Martínez GJ; Celermajer DS; Patel S Atherosclerosis; 2018 Feb; 269():262-271. PubMed ID: 29352570 [TBL] [Abstract][Full Text] [Related]
33. Atherosclerosis and interferon-γ: new insights and therapeutic targets. Voloshyna I; Littlefield MJ; Reiss AB Trends Cardiovasc Med; 2014 Jan; 24(1):45-51. PubMed ID: 23916809 [TBL] [Abstract][Full Text] [Related]
34. Novel anti-inflammatory therapies for the treatment of atherosclerosis. Khan R; Spagnoli V; Tardif JC; L'Allier PL Atherosclerosis; 2015 Jun; 240(2):497-509. PubMed ID: 25917947 [TBL] [Abstract][Full Text] [Related]
35. Macrophages and dendritic cells: the usual suspects in atherogenesis. Kassiteridi C; Monaco C Curr Drug Targets; 2015; 16(4):373-82. PubMed ID: 25808566 [TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory and immune-modulatory therapies for preventing atherosclerotic cardiovascular disease. Yamashita T; Sasaki N; Kasahara K; Hirata K J Cardiol; 2015 Jul; 66(1):1-8. PubMed ID: 25744783 [TBL] [Abstract][Full Text] [Related]
37. Development of anti-atherosclerosis therapy based on the inflammatory and proliferative aspects of the disease. Maranhão RC; Leite AC Curr Pharm Des; 2015; 21(9):1196-204. PubMed ID: 25312729 [TBL] [Abstract][Full Text] [Related]
38. Inflammation in Atherosclerosis-No Longer a Theory. Libby P Clin Chem; 2021 Jan; 67(1):131-142. PubMed ID: 33393629 [TBL] [Abstract][Full Text] [Related]
39. [Current studies of cytokines in the pathogenesis of atherosclerosis and its therapeutic measures]. Li ZM; Wang MJ Sheng Li Xue Bao; 2021 Jun; 73(3):501-508. PubMed ID: 34230951 [TBL] [Abstract][Full Text] [Related]